Search This Blog

Thursday, November 6, 2025

ACADIA Pharmaceuticals Inc (ACAD) Q3 2025 Earnings Call Highlights: Record Sales

 

Positive Points

  • ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) reported total revenues of $278.6 million for the third quarter, marking an 11% increase from the previous year.

  • DAYBUE achieved its highest net sales in a single quarter at $101.1 million, with over 1,000 unique patients globally receiving the treatment.

  • NUPLAZID delivered record net sales of $177.5 million, representing a 12% year-over-year growth driven by a 9% increase in volume.

  • The company initiated a Phase 2 study for ACP-204 in Lewy Body Dementia Psychosis and a Phase 3 study of trofinetide in Japan, indicating strong pipeline progress.

  • ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) ended the quarter with $847 million in cash, up from $762 million at the end of the second quarter, showcasing strong financial health.

Negative Points

  • Despite progress, DAYBUE's market penetration remains relatively low at about 40% in the US and only 27% in the community setting.

  • Penetration among patients older than 11 years is significantly lower, indicating a potential challenge in expanding the treatment's reach.

  • The company faces increased R&D expenses, which rose to $87.8 million in the third quarter, primarily due to higher clinical trial expenses.

  • ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) had a disappointing outcome in their Prader-Willi syndrome study, which did not meet expectations.

  • The company is making significant investments in expanding its field force, which could increase operational costs and impact short-term profitability.

AstraZeneca drops MASH drug over disappointing phase 2 data

 AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a phase 2 study.

The U.K.-based pharma had been evaluating the antisense oligonucleotide, dubbed AZD2693, in a phase 2b study of patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.

The study had been due to read out in the third quarter of the year, but AstraZeneca disclosed in its third-quarter earnings documents (PDF) this morning that the trial has been “discontinued due to efficacy.”

Dropping AZD2693 is unlikely to impact AstraZeneca’s wider MASH ambitions, however. The company also has a phase 1-stage GLP-1 agonist that’s being assessed for the liver disease as well as a FAP inhibitor called AZD2389 that’s due to read out later this year.

The other phase 2 asset AstraZeneca dropped this morning was less of a surprise. The pharma confirmed it has ended work on a Takeda-partnered drug for multiple system atrophy, a rare condition that's caused by a loss of nerve cells in the brain.

Takeda had been assessing the alpha-synuclein antibody, called TAK-341 or MEDI1341, in a global study of 159 patients. But the Japanese drugmaker revealed last week that the study failed to hit its primary or secondary endpoints.

Further back in AstraZeneca’s pipeline, the company disclosed today that it has ended work on two phase 1-stage oncology assets “due to strategic portfolio prioritisation.”

One of these was AZD0022, an oral KRASG12D inhibitor that was being assessed in an early-stage study of 430 patients with colorectal cancer, pancreatic ductal adenocarcinoma and non-small cell lung cancer.

The other was AZD9829, an anti-CD123/TOP1i antibody-drug conjugate being evaluated in patients with acute myeloid leukemia and myelodysplastic syndromes.

While AstraZeneca has tasted ADC success with Daiichi Sankyo thanks to Enhertu and its follow-up Datroway, the U.K.-based Big Pharma has decided to go it alone as it explores the next generation of ADCs. 

https://www.fiercebiotech.com/biotech/astrazeneca-drops-phase-2-stage-mash-drug-over-disappointing-data

'Nvidia’s Jensen Huang softens his ‘China will win the AI race’ remark to FT'

 Nvidia CEO Jensen Huang reportedly told the Financial Times on Wednesday that “China is going to win the AI race,” only to release a notably softer statement soon after. 

The prolific tech leader was speaking on the sidelines of the FT’s Future of AI Summit, where he warned that China would beat the U.S. in artificial intelligence thanks to lower energy costs and looser regulations.

The comments, which CNBC could not verify independently, would represent Huang’s starkest warning yet that the U.S. is at risk of losing its global lead in advanced AI technologies. 

However, several hours after the FT published its report, Nvidia issued a separate statement from Jensen on an official X account. 

“As I have long said, China is nanoseconds behind America in AI. It’s vital that America wins by racing ahead and winning developers worldwide,” he added.

Huang has long stated that the U.S. can stay ahead in the AI race if it keeps developers reliant on Nvidia’s leading AI chips — an argument the CEO has used to lobby against export restrictions on his company’s sales to China. 

Following meetings with U.S. President Donald Trump in July, it seemed that Huang’s efforts had paid off, with Washington agreeing to ease some of its chip curbs. 

Under the plan, Nvidia and competing AI chip company AMD had agreed to pay the U.S. government 15% of their Chinese revenues from sales of existing AI processors tailored for the market.

However, Beijing has since shut Nvidia out of the market as it conducts a national security review of its chips, with Huang stating that the firm’s market share has been reduced to zero

It remains unclear whether China will allow any of Nvidia’s chips to return, as officials push domestic tech companies towards its domestic AI chip alternatives. However, some experts have speculated that Beijing is using Nvidia’s market access as leverage in trade negotiations or to push Washington for wider access to advanced semiconductors.

Huang was in South Korea last month, during Trump’s meeting with Chinese President Xi Jinping. Highly anticipated trade talks between the two leaders did not yield any concessions from either side on chip policy. 

According to The Wall Street Journal, Trump had initially sought to discuss a request by Huang to allow sales of a new generation of AI chips to China. However, top officials rallied against the idea, the Journal reported, citing anonymous current and former administration officials familiar with the matter.

Now that Nvidia’s access to China remains frozen, it appears Huang is shifting his attention to other matters he considers essential to Nvidia’s growth and the AI race. 

In the interview with the FT, Huang reportedly expressed concerns that the West, including the U.S, was being held back by “cynicism” and excessive regulation — contrasting that with China’s energy subsidies aimed at lowering costs for local developers using domestic chips.

https://www.cnbc.com/2025/11/06/jensen-huang-says-china-will-win-the-ai-race-before-clarifying-in-a-statement-nvidia-trump-xi.html